OOIR: Observatory of International Research

Papers

(The TQCC of Experimental Hematology & Oncology is 13. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-05-01 to 2024-05-01.)

Article	Citations
Complex roles of cAMP–PKA–CREB signaling in cancer	212
CD44 as a tumor biomarker and therapeutic target	182
Leukemia incidence trends at the global, regional, and national level between 1990 and 2017	122
Risk factors and outcome of COVID-19 in patients with hematological malignancies	110
Research progress on dendritic cell vaccines in cancer immunotherapy	65
SARS-CoV-2 induced thrombocytopenia as an important biomarker significantly correlated with abnormal coagulation function, increased intravascular blood clot risk and mortality in COVID-19 patients	65
Engineering better chimeric antigen receptor T cells	64
Predictive biomarkers of anti-PD-1/PD-L1 therapy in NSCLC	63
A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017	63
YTHDF1 promotes hepatocellular carcinoma progression via activating PI3K/AKT/mTOR signaling pathway and inducing epithelial-mesenchymal transition	56
Role of m6A writers, erasers and readers in cancer	55
Macrophage, the potential key mediator in CAR-T related CRS	54
Roles of tumor-associated macrophages in tumor progression: implications on therapeutic strategies	54
MiRNA-mediated EMT and CSCs in cancer chemoresistance	48
Heterogeneity of the tumor immune microenvironment and its clinical relevance	46
Microenvironment characterization and multi-omics signatures related to prognosis and immunotherapy response of hepatocellular carcinoma	45
Current advances and challenges in CAR T-Cell therapy for solid tumors: tumor-associated antigens and the tumor microenvironment	44
Recent advances and challenges of bispecific antibodies in solid tumors	43
AP-1 family transcription factors: a diverse family of proteins that regulate varied cellular activities in classical hodgkin lymphoma and ALK+ ALCL	43
VEXAS syndrome in myelodysplastic syndrome with autoimmune disorder	42
Interleukin-6-knockdown of chimeric antigen receptor-modified T cells significantly reduces IL-6 release from monocytes	41
COVID-19 vaccination associated severe immune thrombocytopenia	37
Breast cancer heterogeneity and its implication in personalized precision therapy	36
Targeting PD-1/PD-L1 pathway in myelodysplastic syndromes and acute myeloid leukemia	35
Natural killer cells associated with SARS-CoV-2 viral RNA shedding, antibody response and mortality in COVID-19 patients	35

Leukemia stem cell-bone marrow microenvironment interplay in acute myeloid leukemia development	35
Blocking siglec-10hi tumor-associated macrophages improves anti-tumor immunity and enhances immunotherapy for hepatocellular carcinoma	35
Etanercept as a new therapeutic option for cytokine release syndrome following chimeric antigen receptor T cell therapy	33
PCSK9 promotes tumor growth by inhibiting tumor cell apoptosis in hepatocellular carcinoma	32
Current insight into the regulation of PD-L1 in cancer	32
Exosomes from BM-MSCs promote acute myeloid leukemia cell proliferation, invasion and chemoresistance via upregulation of S100A4	31
m6A binding protein YTHDF2 in cancer	30
Belinostat in combination with standard cyclophosphamide, doxorubicin, vincristine and prednisone as first-line treatment for patients with newly diagnosed peripheral T-cell lymphoma	29
MET amplification identified by next-generation sequencing and its clinical relevance for MET inhibitors	29
The role of neutrophil extracellular traps in cancer progression, metastasis and therapy	28
Progress in understanding the mechanisms of resistance to BCL-2 inhibitors	28
Roles of the intestinal microbiota and microbial metabolites in acute GVHD	28
Pan-cancer analysis reveals tumor-associated macrophage communication in the tumor microenvironment	27
TCR engineered T cells for solid tumor immunotherapy	27
Recent advances in Lynch syndrome	27
The global, regional, and national burden of kidney cancer and attributable risk factor analysis from 1990 to 2017	26
Correlation of mutational landscape and survival outcome of peripheral T-cell lymphomas	24
TRIM family contribute to tumorigenesis, cancer development, and drug resistance	24
The frequency and inter-relationship of PD-L1 expression and tumour mutational burden across multiple types of advanced solid tumours in China	22
Increasing cure rates of solid tumors by immune checkpoint inhibitors	22
Expression differences of miR-142-5p between treatment-naïve chronic myeloid leukemia patients responding and non-responding to imatinib therapy suggest a link to oncogenic ABL2, SRI, cKIT and MCL1 si	22
Distinction between clonal and paraclonal cutaneous involvements in VEXAS syndrome	22
Molecular drivers and cells of origin in pancreatic ductal adenocarcinoma and pancreatic neuroendocrine carcinoma	21
Comprehensive analysis of clinical, pathological, and genomic characteristics of follicular helper T-cell derived lymphomas	21
Tumor mutation burden estimated by a 69-gene-panel is associated with overall survival in patients with diffuse large B-cell lymphoma	21
Advances of target therapy on NOTCH1 signaling pathway in T-cell acute lymphoblastic leukemia	21
Circulating RNA biomarkers in diffuse large B-cell lymphoma: a systematic review	20
A comprehensive model to predict severe acute graft-versus-host disease in acute leukemia patients after haploidentical hematopoietic stem cell transplantation	20
Trends in disease burden of chronic myeloid leukemia at the global, regional, and national levels: a population-based epidemiologic study	20
A novel and efficient CD22 CAR-T therapy induced a robust antitumor effect in relapsed/refractory leukemia patients when combined with CD19 CAR-T treatment as a sequential therapy	20
IPSS-M has greater survival predictive accuracy compared with IPSS-R in persons ≥ 60 years with myelodysplastic syndromes	19
Serologic response and safety of COVID-19 vaccination in HSCT or CAR T-cell recipients: a systematic review and meta-analysis	19
Understanding the versatile roles and applications of EpCAM in cancers: from bench to bedside	19
Myeloid-derived suppressor cells in hematologic malignancies: two sides of the same coin	19
Spindle and kinetochore-associated complex subunit 3 could serve as a prognostic biomarker for prostate cancer	19
Atezolizumab plus bevacizumab combination enables an unresectable hepatocellular carcinoma resectable and links immune exclusion and tumor dedifferentiation to acquired resistance	19
Tanshinone IIA attenuates the stemness of breast cancer cells via targeting the miR-125b/STARD13 axis	18
The degree of microsatellite instability predicts response to PD-1 blockade immunotherapy in mismatch repair-deficient/microsatellite instability-high colorectal cancers	18
Gut fungi enhances immunosuppressive function of myeloid-derived suppressor cells by activating PKM2-dependent glycolysis to promote colorectal tumorigenesis	18
Novel treatment combining antiviral and neutralizing antibody-based therapies with monitoring of spike-specific antibody and viral load for immunocompromised patients with persistent COVID-19 infectio	17
SEPHS1 promotes SMAD2/3/4 expression and hepatocellular carcinoma cells invasion	16
Molecular insights into pathogenesis and targeted therapy of peripheral T cell lymphoma	16
Role of the lectin pathway of complement in hematopoietic stem cell transplantation-associated endothelial injury and thrombotic microangiopathy	16
p53 amyloid aggregation in cancer: function, mechanism, and therapy	16
Learn from antibody–drug conjugates: consideration in the future construction of peptide-drug conjugates for cancer therapy	16
Modified dendritic cell-derived exosomes activate both NK cells and T cells through the NKG2D/NKG2D-L pathway to kill CML cells with or without T315I mutation	16
Chimeric antigen receptor-engineered NK cells: new weapons of cancer immunotherapy with great potential	16
The metabolic adaptation mechanism of metastatic organotropism	16
Function and clinical significance of N6-methyladenosine in digestive system tumours	16
Recent updates for antibody therapy for acute lymphoblastic leukemia	15

Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: lisocabtagene maraleuce	15
Platelet-driven coagulopathy in COVID-19 patients: in comparison to seasonal influenza cases	15
Targeting metabolic reprogramming in chronic lymphocytic leukemia	14
Hypoxia-associated circPRDM4 promotes immune escape via HIF-1α regulation of PD-L1 in hepatocellular carcinoma	14
RHO GTPase family in hepatocellular carcinoma	14
A pan-cancer analysis of the oncogenic role of leucine zipper protein 2 in human cancer	14
METTL3 modulates m6A modification of CDC25B and promotes head and neck squamous cell carcinoma malignant progression	14
Frontiers in the COVID-19 vaccines development	14
Applications of gut microbiota in patients with hematopoietic stem-cell transplantation	14
ALKBH5 prevents hepatocellular carcinoma progression by post-transcriptional inhibition of PAQR4 in an m6A dependent manner	14
CD7-directed CAR T-cell therapy: a potential immunotherapy strategy for relapsed/refractory acute myeloid leukemia	13
Introducing AI to the molecular tumor board: one direction toward the establishment of precision medicine using large-scale cancer clinical and biological information	13
Identification of potential resistance mechanisms and therapeutic targets for the relapse of BCMA CAR-T therapy in relapsed/refractory multiple myeloma through single-cell sequencing	13
The GPIb-IX complex on platelets: insight into its novel physiological functions affecting immune surveillance, hepatic thrombopoietin generation, platelet clearance and its relevance for cancer devel	13
Elevated LDH greater than 400 U/L portends poorer overall survival in diffuse large B-cell lymphoma patients treated with CD19 CAR-T cell therapy in a real world multi-ethnic cohort	13
19-Hydroxybufalin inhibits non-small cell lung cancer cell proliferation and promotes cell apoptosis via the Wnt/β-catenin pathway	13
Targeting phosphoglycerate dehydrogenase in multiple myeloma	13
Pancreatic cancer resistance conferred by stellate cells: looking for new preclinical models	13
Targeting phosphoinositide 3-kinases and histone deacetylases in multiple myeloma	13
Involvement of classic and alternative non-homologous end joining pathways in hematologic malignancies: targeting strategies for treatment	13